STK-012 is an α/β biased IL-2 partial agonist designed to stimulate antigen-activated T cells while avoiding IL-2 associated toxicities Positive Phase 1b data recently presented at SITC 2025, with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results